HMC
QNCX icon

Harvard Management Company’s Quince Therapeutics QNCX Stock Holding History

Harvard Management Company’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15
Closed -$156K – 46
2021
Q2 		$156K Buy
+15
New +$126K 0.01% 38

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Harvard Management Company's QNCX Position: Q3 2021 in Review

Harvard Management Company sold out of Quince Therapeutics (QNCX) in Q3 2021, closing a stake of 15 shares — an estimated $156K sold.

Harvard Management Company first reported a position in QNCX in Q2 2021 and held it in 1 quarter. The position peaked at $156K in Q2 2021. 126 funds tracked by Wall St. Rank hold QNCX as of Q3 2021.

  • Harvard Management Company reported no remaining Quince Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Harvard Management Company sold 15 Quince Therapeutics shares in Q3 2021, an estimated $156K.
  • Harvard Management Company first reported a position in Quince Therapeutics in Q2 2021 and held it in 1 quarter.
  • Harvard Management Company's Quince Therapeutics position peaked at $156K in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2021.

Based on Harvard Management Company's 13F filing for Q3 2021, filed 12 Nov 2021.